Cancer Immunotherapy
- 1st Edition, Volume 209 - October 24, 2024
- Editor: David B. Teplow
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 2 3 5 3 4 - 4
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 3 5 3 5 - 1
Cancer Immunotherapy, Volume 209 covers the progress that has been made in cancer immunotherapy. This volume surveys exciting developments in the field while also highli… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteOther chapters cover Magnetic Nanoparticles: An Emerging Nanomedicine for Cancer Immunotherapy and Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment.
- Discusses immune surveillance of tumors and how it is compromised
- Presents new approaches to the development and delivery of cancer vaccines and cytotoxic T-cells to the tumor site
- Demonstrates how new molecular biological approaches may augment the efficacy of CAR-T cells and dampen the effects of non-coding RNAs
- Title of Book
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter One: Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment
- Abstract
- 1 Introduction
- 2 Overview of innate lymphoid cells
- 3 NK cells in cancer pathogenesis and immunotherapy
- 4 ILC1 in tumorigenesis and immunotherapy
- 5 ILC2 in tumorigenesis and cancer immunotherapy
- 6 ILC3 in tumorigenesis and potential immunotherapeutic strategies
- 7 Concluding remarks
- References
- Chapter Two: Breakthroughs in synthetic controlling strategies for precision in CAR-T therapy
- Abstract
- 1 Introduction
- 2 Optimising the delivery and expression of CAR
- 3 Regulation of CAR expression and function
- 4 Outlook
- References
- Chapter Three: Rational design of adjuvants boosts cancer vaccines
- Abstract
- 1 Introduction
- 2 Basic knowledge about cancer vaccines
- 3 Classification of adjuvants in cancer vaccines
- 4 Factors affecting adjuvants properties in cancer vaccines
- 5 Prospects
- Acknowledgements
- References
- Chapter Four: The promise, progress, and challenges of in situ immunization agents in cancer immunotherapy
- Abstract
- 1 Introduction
- 2 History
- 3 General principles of mechanism in the context of the cancer-immunity cycle
- 4 Approaches and modalities
- 5 Clinical considerations
- 6 Concluding remarks
- References
- Chapter Five: Emerging drug delivery systems to alter tumor immunosuppressive microenvironment: Overcoming the challenges in immunotherapy for glioblastoma
- Abstract
- Abbreviations
- 1 Introduction
- 2 The immune system
- 3 Failure of immune system: cancer cells evading the immune surveillance and tumor
- 4 Delivery systems with the potential to alter TIME
- 5 Conclusion
- References
- Chapter Six: Magnetic nanoparticles: An emerging nanomedicine for cancer immunotherapy
- Abstract
- 1 Introduction
- 2 The physicochemical properties of magnetite (Fe3O4) nanoparticles
- 3 The factors influencing the pharmacokinetics of MNPs
- 4 MNPs and immunotherapy
- 5 Conclusion
- References
- Chapter Seven: Non-coding RNAs in cancer immunotherapy: A solution to overcome immune resistance?
- Abstract
- 1 Introduction
- 2 ncRNAs
- 3 Non-coding RNAs and immune cells in the tumor microenvironment
- 4 ncRNAs can be applied to monitor tumor microenvironment and predict response to immunotherapy and patients’ survival
- 5 ncRNA-based immunotherapy can improve response to ICIs and other methods of immunotherapy
- 6 Conclusion
- References
- Chapter Eight: Immunotherapy outcomes in non-small cell lung cancer according to a gender perspective
- Abstract
- 1 Introduction
- 2 Sex differences in immune system, hormonal influences and impact of smoking status
- 3 Sex differences in immune system of cancer patients
- 4 Current studies about immunotherapy approaches in lung cancer according to sex
- 5 Conclusions
- References
- Index
- No. of pages: 300
- Language: English
- Edition: 1
- Volume: 209
- Published: October 24, 2024
- Imprint: Academic Press
- Hardback ISBN: 9780443235344
- eBook ISBN: 9780443235351
DT
David B. Teplow
David B. Teplow, Ph.D., is a Professor of Neurology, Emeritus, at UCLA and an internationally recognized leader in efforts to understand and treat Alzheimer's disease. Dr. Teplow's group has used a multi-disciplinary approach to determine how neurotoxic peptides, such as the amyloid β-protein (Alzheimer's disease) and α-synuclein (Parkinson’s disease), form neurotoxic structures that kill neurons and to develop the means to block these processes. Dr. Teplow received undergraduate training at UC Berkeley; a Ph.D. from the University of Washington; and was a postdoctoral scholar at Caltech. Before coming to UCLA, Dr. Teplow was a faculty member in the Department of Neurology, Harvard Medical School. Dr. Teplow has published >250 peer-reviewed articles, books and book chapters, and commentaries, in addition to serving on numerous national and international scientific advisory boards. Dr. Teplow was a founding editor of the Journal of Molecular Neuroscience and Current Chemical Biology, He is Co-Editor-in-Chief of the Elsevier serial Progress in Molecular Biology and Translational Science and is Associate Editor-in-Chief of the American Journal of Neurodegenerative Disease.